COMPANY

Q Therapeutics

Keywords: neurology cell therapy neurodegenerative diseases Transverse Myelitis Amyotrophic Lateral Sclerosis Q-Cells

Profile checked Oct 10, 2026

Timeline

2026-12 Trial start Phase 1/Phase 2: Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (AL source ↗
Sep 20, 2022 Trial start Phase 1/Phase 2: Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis source ↗

2027-07 (ESTIMATED) · Phase 1/Phase 2 · Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis · NCT03887273
2028-12 (ESTIMATED) · Phase 1/Phase 2 · Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) · NCT02478450

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT03887273	Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis	Phase 1/Phase 2	Recruiting	Sep 20, 2022	2027-07 (estimated)
NCT02478450	Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)	Phase 1/Phase 2	Not yet recruiting	2026-12	2028-12 (estimated)

Annual award amounts. Total $245K.

Apr 26, 2010 NIH award 1R43NS067719-01 FY2010: $118,355 awarded for that fiscal year; activity R43 (SBIR); PI SANDROCK, ROBERT WAYNE; recipient as written: Q THERAPEUTICS, INC., SALT LAKE CITY, UT. Development of Astrocyte-Restri source ↗
Sep 18, 2004 NIH award 1R43NS048651-01 FY2004: $126,563 awarded for that fiscal year; activity R43 (SBIR); PI RAMASWAMI, MANI; recipient as written: Q THERAPEUTICS, INC., SALT LAKE CITY, UT. A novel technology for protein deliver source ↗